Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam

Summary

The purpose of this study is to determine the safety and tolerability of PA-824 when given with a single dose of midazolam, and to determine whether PA-824 inhibits CYP3A to a clinically important degree as measured by the effect of PA-824 on the pharmacokinetics of midazolam, a known CYP3A substrate.

Timeline

Start

2009-12

Primary completion

2010-01

Completion

2010-04

Drugs

Indications